GT Biopharma (GTBP) Stock Price, News & Analysis

Company Overview

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). Beyond GTB-3550, GT Biopharma is advancing a pipeline of preclinical TriKE constructs aimed at both hematologic and solid tumors, as well as exploring applications in infectious diseases. The modular nature of the TriKE platform enables rapid development of new molecules targeting diverse antigens, supporting strategic combination therapies and expansion into multiple oncology indications.

Founded in 2015 with technology originally licensed from the National Institutes of Health, GT Biopharma is headquartered in Tempe, Arizona, and conducts research and development operations in the United States. The company collaborates with leading academic institutions and global clinical sites to advance its pipeline. Under the leadership of President and CEO Scott K. Koenig, GT Biopharma continues to pursue its mission of delivering next-generation cell-engaging therapies to improve outcomes for patients with cancer and beyond.

Key Stats

• Today's Range: $0.27 to $0.29
• 50-Day Range: $0.28 to $0.51
• 52-Week Range: $0.26 to $1.48
• Volume: 535,620 shs
• Average Volume: 464,359 shs
• Market Capitalization: $12.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

GT Biopharma Stock Analysis - MarketRank™

GT Biopharma scored higher than 8% of companies evaluated by MarketBeat, and ranked 880th out of 909 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

GT Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

GT Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GT Biopharma are expected to grow in the coming year, from ($0.34) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GT Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GT Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GT Biopharma has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.94% of the float of GT Biopharma has been sold short.

Short Interest Ratio / Days to Cover

GT Biopharma has a short interest ratio ("days to cover") of 7.75.

Change versus previous month

Short interest in GT Biopharma has recently decreased by 18.10%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GT Biopharma does not currently pay a dividend.

Dividend Growth

GT Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.13

News Sentiment

GT Biopharma has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for GT Biopharma this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for GTBP on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GT Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.18% of the stock of GT Biopharma is held by insiders.

Percentage Held by Institutions

8.15% of the stock of GT Biopharma is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 8/18/2026
• Corporate presentation: 8/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GTBP
• Previous Symbol: OTCMKTS:OXISD
• CIK: 109657
• Web: www.gtbiopharma.com
• Phone: (415) 919-4040
• Fax: N/A
• Employees: 8
• Year Founded: 1965

Profitability

• EPS (Trailing Twelve Months): ($5.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -194.73%
• Return on Assets: -142.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.14
• Quick Ratio: 4.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.01 per share
• Price / Cash Flow: 19.79
• Book Value: $0.23 per share
• Price / Book: 1.20

Miscellaneous

• Outstanding Shares: 44,340,000
• Free Float: 43,816,000
• Market Cap: $12.21 million
• Optionable: No Data
• Beta: 0.90